Pulmatrix Q3: Cash Down to $1.4M, Going Concern, Merger Closing by Year-End
PULM sits 37% above its 52-week low of $1.06.
Summary
Pulmatrix reported Q3 2026 results with cash down to $1.4 million, a going-concern assumption, and a merger with Eos SENOLYTIX now expected to close by year-end pending Nasdaq listing approval and the approved reverse split.
Key Events · Earnings and Guidance · PULM
-
Q3 Cash Falls to $1.4 Million
Cash and cash equivalents were $1.4 million at September 30, 2026, down from $4.1 million at December 31, 2025, with another $0.7 million in restricted cash that becomes unrestricted only on or around the merger closing.
-
Going-Concern Assumption Disclosed
The unaudited financial statements were prepared assuming the Company continues as a going concern, and management says current cash funds operations only through the anticipated close of the Eos SENOLYTIX merger.
-
Q3 Loss $1.2 Million
Net loss was $1.2 million ($0.34 per share) for the quarter and $3.4 million ($0.95 per share) for the nine months; G&A rose about $0.4 million to $1.2 million on merger-related legal and professional costs while R&D was under $0.1 million.
-
Merger Guided to Close by Year-End
The Eos SENOLYTIX merger is now expected to close in November 2026 or by year-end, subject to Nasdaq approval of the listing of merger shares, completion of the reverse stock split approved October 26, 2026, and customary closing conditions.
Analysis · PULM · Life Sciences
Pulmatrix ended September 30 with $1.4 million in cash plus $0.7 million of restricted cash that frees up only on or around the merger closing, against $4.1 million at the start of the year. The company states its unaudited financials were prepared assuming it continues as a going concern, and that current cash funds operations only through the anticipated close of the Eos SENOLYTIX merger. That makes the deal the whole thesis: management now guides the close to November 2026 / by year-end, contingent on Nasdaq listing approval and the reverse stock split stockholders already approved on October 26. If either slips, there is no disclosed funding backstop beyond the $1.0 million Series B private placement struck back in March.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PULM was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9M. The 52-week trading range was $1.06 to $4.98. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.